MMEDMiniMed Group, Inc.
Price
End-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, the market undecided.
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. We were the first player in the market to commercialize all parts of an integrated diabetes management system.
In the company’s own words · 10-K filed Jun 29, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
MiniMed Group, Inc. (MMED) reported revenue of $843M in Q1 2027 (quarter ended Jul 31, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 55% and net income of $0. For the full year FY2026, revenue was $3.10B (+14% year on year) and net income −$333M. Its largest product in Q3 2026 (quarter ended Jan 23, 2026) was Continuous Glucose Monitoring Systems CGM at $390M, 49% of the disclosed total, ahead of Consumables at 31%. The next results filing is expected around Dec 1, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 2026MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration.Earnings release · press release
- Aug 5, 2026On July 30, 2026, Courtney Nelson Wills, Senior Vice President, General Counsel and Corporate Secretary, notified MiniMed Group, Inc. (“MiniMed”) of her decision to resign from her position, effective September 25, 2026, following an 8-week transition period.Director or officer change · Form 8-K
- Jun 29, 2026On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2026 · $790.0MThe company’s own SEC segment disclosure.
- Continuous Glucose Monitoring Systems CGM$390.0M49%
- Consumables$244.0M31%
- Pumps$151.0M19%
- Product And Service Other$5.0M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
The closest names by size in the same industry